TruAlt Bioenergy FY26 profits drop to ₹8,983 lakhs
Standalone revenue fell 9% as earnings per share halved to ₹10.23.
— 3 earlier stories on TruAlt Bioenergy Ltd. →What's new
- Standalone revenue fell to ₹1,70,405 lakhs from ₹1,88,012 lakhs.
- Earnings per share dropped to ₹10.23, down from ₹20.08 last year.
- The board re-confirmed stakes held by GAIL and Sumitomo Corp.
Why this matters
The company's core profitability is shrinking rapidly. Strategic partnerships exist, but they have yet to arrest the slide in earnings.
What we're watching
- Ethanol supply contract performance under the 90-day extension.
- The impact of the Honeywell SAF technology deal on FY27 margins.
- Whether the company stabilizes operating costs next quarter.
The full read
TruAlt Bioenergy ended FY2026 with a sharp reversal in financial health. Standalone revenue contracted to ₹1,70,405 lakhs from the prior year's ₹1,88,012 lakhs. Net profit took a harder hit, dropping to ₹8,983 lakhs from ₹14,862 lakhs. Shareholders saw earnings per share nearly halve to ₹10.23. The filing repeated details on external stakes held by GAIL and Sumitomo Corporation, alongside a Honeywell SAF technology deal. It also noted a 90-day extension for an ethanol supply contract worth ₹1,675 crore. These items were already known. They offer no cover for the current bottom-line erosion. The auditor report arrived with no modifications. The performance is weak. The firm now needs to prove it can turn its technology and supply-side agreements into actual margins before the next cycle hits.
TruAlt Bioenergy Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on TRUALT →- 22 May 2026 · 5:05 PM IST TruAlt Bioenergy FY26 profits drop to ₹8,983 lakhs
- 24d ago TruAlt Bioenergy lands ₹150 cr government grant for SAF plant
- 51d ago TruAlt Bioenergy pushes back SAF project as ethanol volumes miss targets
- 51d ago TruAlt Bioenergy's profit halves as revenue drops; no new catalysts in filing